| 17th June - 17h45 |
PROGRESS IN ENDOCRINE TREATMENTS FOR BREAST CANCER
Chairman: M. Colleoni
Refining diagnostics: accurate definition of endocrine responsiveness – G. Viale
Improving performance of Aromatase Inhibitors –A. Coates
Supported by Novartis |
| 17th June – 18h45 |
EFFICACY AND SAFETY OF ANTHRACYCLINES IN THE TREATMENT OF HER2+ BREAST CANCER
Chairman: V. Lorusso
Role of topo II-alpha on predicitng sensitivity to anthracyclines in the treatment of HER2+ Breast Cancer - A. Di Leo
New Opportunities in the combination of Anthracyclines and anti-HER2 Agents - C. Tondini
Supported by Cephalon |
| 18th June – 10h20 |
METRONOMIC VINORELBINE: AN ANTIANGIOGENIC DRUG?
Chairman: S. Cinieri
Speaker: F. Nolé
Supported by Pierre Fabre Pharma |
| 18th June – 13h00 |
IMPROVING ANTI HER2 THERAPY IN BREAST CANCER.
Chairman: A. Goldhirsch
How can we overcome resistance in trastuzumab pretreated patients? - A. Di Leo
Lapatinib in HER2+ Metastatic Breast Cancer – P. Pronzato
Supported by GlaxoSmithKline |
| 18th June – 16h30 |
LHRHa in pre-menopausal women with Breast Cancer:
- with TAM
- with AIs
- and as protection of ovarian function from chemotherapy-induced damage
Chairman: S. Barni
Speaker: L. Del Mastro
Supported by Ipsen |
| 18th June - 18h00 |
BEYOND CONVENTIONAL CHEMOTHERAPY
Chairman: E. Winer
How can we enhance anti angiogenesis treatment? The particular case of SDF1 protein – F. Bertolini
Treat patients only with biological therapy: myth and reality – I. E. Smith
Supported by Roche |
| 19th June 2009 - 07h30 |
CIRCULATING TUMOR CELLS IN THE CLINICAL MANAGEMENT OF BREAST CANCER PATIENTS AT DIFFERENT STAGES RECEIVING CHEMOTHERAPY
Chairman: M. T. Sandri
Circulating tumor cell detection during neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial
J. Y. Pierga
Circulating tumor cells as valuable tool for more individualized treatment approaches in primary breast cancer? - Results from the adjuvant SUCCESS Trials"
B. Rack
Supported by Veridex |
| 19th June - 10h15 |
The importance of carry over effect in post menopausal women with Breast Cancer
Chairman: Dott. Saverio Cinieri
Speaker: Dott. Vito Lo Russo |
| 19th June – 12h45 |
HER2/NEU POSITIVE PATIENTS: FROM NOW TO THE FUTURE
Chairman: Saverio Cinieri
From candidate to responsible patients: the case of Her2/neu positive tumours.
Giuseppe Viale
Open questions on adjuvant setting: the key for the future
Michele de Laurentiis
Supported by Roche |
